Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...

The world just got a little closer. The new iGlobal Radio App is now live, offering users a dynamic way to connect with radio ...

Spinal Simplicity, a medical device company dedicated to creating simple, innovative procedure solutions, is proud to announce the launch of the Patriot-SI implant as a stand-alone solution for ...

Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.

In a precedential decision issued June 4, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed a district court's finding of noninfringement in favor of Moderna, Inc. in its ongoing ...

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated ...

CAMBRIDGE, Mass., May 28, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman ...